Related Experiment Video
Updated: Feb 19, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Lupeol restores dopaminergic function by suppressing glial activation in a Parkinson's disease mouse model
Riaz Ahmad1, Kyonghwan Choe1,2, Hyun Young Park2,3
1Division of Life Sciences and Applied Life Science (BK 21 Four), College of Natural Science, Gyeongsang National University, Jinju, Republic of Korea.
Introduction:
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by chronic neuroinflammation and loss of dopaminergic neurons. The neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) selectively targets dopaminergic neurons, effectively replicating the pathological features of PD. Lupeol, a natural pentacyclic triterpenoid, has been shown to exhibit neuroprotective properties in various models by reducing oxidative stress, inflammation, and apoptosis. This study aimed to investigate the neuroprotective effects of lupeol in an MPTP-induced mouse model of PD.
Methods:
Male mice were administered MPTP (30 mg/kg, i.p.) for seven days to induce PD-like pathology. Lupeol (50 mg/kg) was administered as a potential therapeutic intervention. Behavioral assessments were conducted to evaluate motor function. Biochemical analyses were performed to measure dopamine and tyrosine hydroxylase (TH) levels. Immunohistochemical and molecular approaches were used to assess glial activation, oxidative stress, and apoptotic signaling pathways in the substantia nigra pars compacta (SNpc) and striatum.
Results:
Lupeol treatment significantly improved MPTP-induced motor impairments and restored dopamine and TH levels. Additionally, lupeol reduced neuroinflammation, by decreasing microglial activation, astrocyte reactivity, and lower levels of inflammatory mediators. Oxidative stress markers, including reactive oxygen species (ROS) and lipid peroxidation (LPO), were diminished in SNpc and striatum following lupeol treatment. Furthermore, lupeol upregulated antioxidant defense mechanisms by increasing the expression of Nrf-2 and HO-1. Apoptotic markers, such as Cytochrome C, Bax, and Caspase-3, were downregulated, indicating reduced neuronal apoptosis.
Conclusion:
The current study suggests that lupeol exerts neuroprotective effects by inhibiting glial cell activation, thereby reducing neuroinflammation, oxidative stress, and apoptosis in an MPTP-induced PD mouse model.
Insights
Lupeol shows neuroprotective effects in a Parkinson's disease mouse model. It reduces inflammation, oxidative stress, and neuronal death, improving motor function and offering potential therapeutic benefits for Parkinson's disease.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD) is characterized by neuroinflammation and dopaminergic neuron loss.
- MPTP toxin models PD pathology by targeting dopaminergic neurons.
- Lupeol, a natural triterpenoid, exhibits known neuroprotective properties.
Purpose of the Study:
- To investigate lupeol's neuroprotective effects in an MPTP-induced mouse model of Parkinson's disease.
- To evaluate lupeol's impact on motor function, neuroinflammation, oxidative stress, and apoptosis in PD models.
Main Methods:
- MPTP administration to induce PD-like pathology in male mice.
- Lupeol administration as a therapeutic intervention.
- Behavioral tests, biochemical assays, and immunohistochemical analyses of the substantia nigra and striatum.
Main Results:
- Lupeol treatment improved motor function and restored dopamine levels.
- Reduced neuroinflammation via decreased microglial and astrocyte activation.
- Diminished oxidative stress markers (ROS, LPO) and apoptotic signaling.
- Upregulated antioxidant defenses (Nrf-2, HO-1).
Conclusions:
- Lupeol demonstrates significant neuroprotective effects in an MPTP-induced PD model.
- Inhibition of glial activation by lupeol reduces neuroinflammation, oxidative stress, and apoptosis.
- Lupeol represents a potential therapeutic agent for Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:15Parkinson's Disease: Overview